Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | TGM2 | P21980 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | GRK2 | P25098 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19707566 | 0.85 | GAA (0.65) | GAATGM2KMT2AALDH1A1MEN1 | |
| SCHEMBL11858223 | 0.84 | GPR35 (0.67) | GAAKMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL29556097 | 0.84 | MAOA (0.69) | GAATGM2KMT2AALDH1A1MEN1 | |
| SCHEMBL2090960 | 0.83 | GAA (0.62) | GAATGM2KMT2AALDH1A1MEN1 | |
| SCHEMBL2085653 | 0.82 | TGM2 (0.66) | GAATGM2KMT2AALDH1A1MEN1 | |
| SCHEMBL167814 | 0.82 | GAA (0.61) | GAATGM2KMT2AALDH1A1MEN1 | |
| SCHEMBL5142687 | 0.82 | GAA (0.77) | GAATGM2KMT2AALDH1A1MEN1 | |
| SCHEMBL264735 | 0.82 | GAA (0.66) | GAATGM2ALDH1A1HPGDP2RX1 | |
| SCHEMBL22191811 | 0.81 | MEN1 (0.78) | KMT2AALDH1A1MEN1LMNAHPGD | |
| SCHEMBL29388992 | 0.81 | GAA (0.70) | GAATGM2KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009087220-A1 | USE OF THIAZOLOIMIDAZOLES, THIAZOLOTETRAZOLES AND THIAZOLOTRIAZOLES AS MGLUR5 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-07-16 | — | — | WO | claimed |
| EP-4519246-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | Prilenia Neurotherapeutics Ltd. (IL) | 2025-03-12 | — | — | EP | disclosed |
| US-20240190883-A1 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4355741-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2023214412-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-11-09 | — | — | WO | disclosed |
| US-11713308-B2 | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-08-01 | — | — | US | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1360211-A2 | NEW POLYMERS BASED ON N-CARBAMYL-N'-DIMETHYLSILYL METHYL-PIPERAZINE TRACELESS LINKERS FOR THE SOLID PHASE SYNTHESIS OF PHENYL BASED LIBRARIES | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-07-17 | — | — | US | disclosed |
| WO-2003055867-A1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2003-07-10 | — | — | WO | disclosed |
| EP-1309575-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | Galderma Research & Development (FR) | 2003-05-14 | — | — | EP | disclosed |
| CN-1390219-A | Pyrazolopyrimidines as therapeutic agents | ABBOTT AG (DE) | 2003-01-08 | — | — | CN | disclosed |
| US-20020120072-A1 | Polymers based on N-carbamyl-N'-dimethysilyl methyl-piperazine traceless linkers for the solid phase synthesis of phenyl based libraries | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-29 | — | — | US | disclosed |
| WO-2002060960-A2 | NEW POLYMERS BASED ON N-CARBAMYL-N'-DIMETHYLSILYL METHYL-PIPERAZINE TRACELESS LINKERS FOR THE SOLID PHASE SYNTHESIS OF PHENYL BASED LIBRARIES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-08 | — | — | WO | disclosed |
| WO-2002012210-A9 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002012210-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | GAA 1393/4885TGM2 1081/4885KMT2A 33/4885 |
| US-20020120072-A1 | Polymers based on N-carbamyl-N'-dimethysilyl methyl-piperazine traceless linkers for the solid phase synthesis of phenyl based libraries | DOT1L, DNMT3L, SMYD2 | GAA 4347/4885TGM2 3644/4885KMT2A 77/4885 |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | GAA 13/4885TGM2 68/4885KMT2A 2286/4885 |
| US-11713308-B2 | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | VAPA, VAPB, SLC10A1 | GAA 441/4885TGM2 315/4885KMT2A 2852/4885 |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | GAA 547/4885TGM2 3063/4885KMT2A 3570/4885 |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | GAA 1254/4885TGM2 1014/4885KMT2A 3061/4885 |
| US-20240190883-A1 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | KRAS, NRAS, APC | GAA 265/4885TGM2 1546/4885KMT2A 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.